Clinical trial
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF PRIFETRASTAT IN PARTICIPANTS WITH MODERATE AND SEVERE RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL RENAL FUNCTION.
NCT07933848 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF PRIFETRASTAT IN PARTICIPANTS WITH MODERATE AND SEVERE RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL RENAL FUNCTION.
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 17, 2026
- Completion date
- May 27, 2028
- Enrollment
- 24 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
healthy adults, renal impairment
Arms
As registered; 3 arms.
-
Moderate Renal Impairment (Cohort 1)
Prifetrastat administered by mouth as a single dose in participants with moderate renal impairment (eGFR = 30-59 mL/min).
-
Severe Renal Impairment (Cohort 2)
Prifetrastat administered by mouth as a single dose in participants with severe renal impairment (eGFR \< 30 mL/min).
-
Normal Renal Function (Cohort 3)
Prifetrastat administered by mouth as a single dose in participants with normal renal function (eGFR ≥ 90 mL/min).
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prifetrastat
-
Maximum Observed Plasma Concentration (Cmax) of Prifetrastat
Lead sponsor's other trials
Pfizer, most recent start first.
+3,332 more trials See the organization page
Similar trials
Same condition (Renal Insufficiency) and phase, most recent start first.
+388 more trials See the condition page